| Date | Title | Description |
| 08.09.2026 | Ascletis Announces Initiation of Phase I Study in U.S. for Oral Amylin Receptor Peptide Agonist ASC36 for the Treatment of Obesity | - This trial marks the fourth Phase I peptide study for Ascletis this year.
- ASC36 oral tablets achieved absolute oral bioavailability of 6% to 8% at steady state in non-human primate (NHP) studies utilizing Ascletis' proprietary Peptide O... |
| 07.09.2026 | Ascletis Announces Inclusion in the Hong Kong Stock Connect List under the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect Programs | HONG KONG, Sept. 7, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that, the ordinary shares of the Company (the "Shares"), which trade on The Stock Exchange of Hong Kong Limited (the "... |
| 30.08.2026 | Ascletis Announces First Participant Dosed in a Global Phase III Clinical Program of Once-Daily Oral Small Molecule GLP-1 Receptor Agonist ASC30 for Chronic Weight Management | - Expected to enroll approximately 4,600 participants with obesity or overweight across two pivotal trials (AURORA-1 and AURORA-2) in the U.S., Europe, and Canada.
- Global Phase III clinical program to investigate efficacy and safety of th... |
| 10.08.2026 | Ascletis Announces Initiation of Two Phase I Studies in U.S. for the Treatment of Obesity: ASC36 Once-Monthly Injection, an Amylin Receptor Peptide Agonist, and ASC36_35FDC Once-Monthly Injection, a C... | -ASC36_35FDC, a once-monthly subcutaneous (SQ) fixed dose combination (FDC) injection of ASC36 and ASC35, is a potentially first-in-class drug candidate which targets three validated targets of amylin receptor, GLP-1R and GIPR.
-ASC36 is a ... |
| 03.08.2026 | Ascletis Announces Initiation of Global Phase III for Oral Small Molecule GLP-1, ASC30 and Positive Preclinical Data for Its First-in-Class Oral Small Molecule GLP-1/GIP/Amylin Fixed-Dose Combination | -Initiated global Phase III program for oral small molecule GLP-1, ASC30, which will enroll approximately 4,600 participants with obesity or overweight across two pivotal trials in the U.S., Europe, and Canada.
-Positive preclinical data in... |
| 27.07.2026 | Ascletis Announces Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, Demonstrated Superior Weight Loss in a Diet-Induced Obese Mouse Model | -ASC37 demonstrated statistically significant 88% greater relative body weight reduction compared to tirzepatide in the diet-induced obese (DIO) mouse model.
-Both ASC37 once-monthly subcutaneous (SQ) formulation and oral formulation will b... |
| 23.07.2026 | Ascletis Announces Oral Discussion of ASC36_35 FDC Preclinical Data Demonstrating Superior Weight Loss to Eloralintide/Tirzepatide Combination at the 62nd European Association for the Study of Diabete... | - Fixed-dose combination of ASC36 and ASC35 (ASC36_35 FDC) demonstrated superior weight loss compared to eloralintide in combination with tirzepatide in a diet-induced obese (DIO) animal model.
HONG KONG, July 23, 2026 /PRNewswire/ -- Ascle... |
| 15.07.2026 | Ascletis Selects for Clinical Development a Fixed-Dose Combination of First-in-Class Oral Small Molecule GIPR Agonist, ASC48, and Oral Small Molecule GLP-1R Agonist, ASC30 | - ASC48 is a potentially first-in-class oral small molecule GIPR agonist.
- ASC48 demonstrated an EC50 of 1 pM in the hGIPR cAMP activation assay, exhibiting greater potency than tirzepatide (EC50 = 3 pM) and is a selective agonist for GIPR... |
| 06.07.2026 | Ascletis Submits Two IND Applications to U.S. FDA for the Treatment of Obesity: ASC36 Once-Monthly Injection, a Peptide Amylin Receptor Agonist, and ASC36_35 FDC Once-Monthly Injection, a Co-Formulati... | - ASC36_35 FDC, a once-monthly subcutaneous (SQ) injection co-formulation of ASC36 and ASC35, is a potentially first-in-class drug candidate targeting three validated targets of amylin receptor, GLP-1R and GIPR.
- ASC36_35 FDC demonstrated ... |
| 23.06.2026 | Ascletis Announces U.S. FDA IND Clearance for Phase I Study of Once-Monthly Subcutaneously Administered GLP-1R/GIPR Dual Peptide Agonist, ASC35, for the Treatment of Obesity | Phase I trial consists of two parts. Part A is a single ascending dose (SAD) study of ASC35 once-monthly Self-Assembling Lipid Depot (SALD) formulation; Part B is a head-to-head study of multiple ascending doses (MAD) of ASC35 once-monthly ... |
| 08.06.2026 | Ascletis Reinforces Its Differentiated Obesity Portfolio at American Diabetes Association (ADA) 2026 Scientific Sessions, Showcasing ASC30 Clinical Data and Exciting Preclinical Findings from ASC37 an... | HONG KONG, June 8, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces the presentation of three key studies at the American Diabetes Association (ADA) 2026 Scientific Sessions (taking place June 5-8, 2026... |
| 06.05.2026 | Ascletis to Present Data on Multiple Programs at the 33rd European Congress on Obesity (ECO 2026) | HONG KONG, May 6, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today poster presentations highlighting multiple programs at the 33rd European Congress on Obesity (ECO 2026), taking place May 12-15, ... |
| 30.04.2026 | Ascletis to Present Data on Multiple Programs at the American Diabetes Association's 2026 Scientific Sessions | HONG KONG, April 30, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today poster presentations highlighting multiple programs at the American Diabetes Association's (ADA's) 2026 Scientific Sessions, t... |
| 27.04.2026 | Ascletis Completes Enrollment in U.S. Phase II Study of ASC30, an Oral Small Molecule GLP-1R Agonist, for the Treatment of Diabetes | - 13-week U.S. Phase II study is evaluating the efficacy, safety and tolerability of oral small molecule GLP-1R agonist ASC30, a once-daily tablet, in 100 participants with diabetes.
- Topline data from the Phase II study are expected in th... |
| 07.04.2026 | Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Deve... | -Fixed-dose combination of ASC30 and ASC39 (ASC30_39 FDC) tablets, dosed orally in dogs, demonstrated comparable pharmacokinetics to those observed in their respective monotherapies in a head-to-head study. The fixed dose combination had ex... |
| 17.03.2026 | Oral Small Molecule Amylin Receptor Agonist ASC39 Demonstrated Eloralintide-like Amylin Selectivity and Efficacy in Preclinical Models | - In a head-to-head cyclic adenosine monophosphate (cAMP) activation assay vs. eloralintide, oral small molecule amylin receptor agonist ASC39 demonstrated similar selectivity and potency to that of eloralintide. EC50 for human amylin 1 rec... |
| 10.03.2026 | Ascletis Announces Positive Topline Results from U.S. Phase II, 24-Week Study for Its Ultra-Long-Acting Subcutaneous Depot Formulations of Small Molecule GLP-1R Agonist ASC30 for Obesity | - ASC30 subcutaneous (SQ) depot formulation achieved statistically significant and clinically meaningful placebo-adjusted mean weight loss of 7.5% at week 16 after three monthly doses.
- ASC30 SQ depot formulation maintained weight loss for... |
| 11.02.2026 | Ascletis Selects Oral Amylin Receptor Peptide Agonist, ASC36, for Clinical Development | - Utilizing Ascletis' Peptide Oral Transport ENhancement Technology (POTENT), ASC36 oral tablets achieved absolute oral bioavailability of 6% to 8% at steady state, in non-human primate (NHP) studies.
- In NHPs, ASC36 oral tablets reduced m... |
| 29.01.2026 | Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne | - Denifanstat (ASC40), a once-daily oral fatty acid synthase (FASN) inhibitor, demonstrated favorable safety and tolerability in a Phase III open-label study
- The exceptional efficacy of denifanstat (ASC40) observed in the Company's previo... |
| 26.01.2026 | Ascletis Announces First Participants Dosed in a 13-week U.S. Phase II Study with ASC30, an Oral Small Molecule GLP-1R Agonist for the Treatment of Diabetes | -Topline data from the Phase II study for the treatment of diabetes are expected in the third quarter of 2026.
-ASC30 demonstrated placebo-adjusted weight loss of up to 7.7% in a recently completed 13-week U.S. Phase II study in participant... |
| 20.01.2026 | Ascletis Selects a Next-Generation Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development | - In head-to-head non-human primate (NHP) studies, average observed half-life of ASC37 was approximately 17 days, 7-fold longer than retatrutide, which supports once-monthly subcutaneous (SQ) dosing in humans.
- ASC37's average in vitro act... |
| 05.01.2026 | Ascletis Announces U.S. FDA IND Clearance for 13-Week Phase II Study of Its Oral Small Molecule GLP-1, ASC30, in Participants with Diabetes | -The Phase II study for diabetes is a 13-week, randomized, double-blind, placebo-controlled and multi-center study to evaluate the efficacy, safety, and tolerability of ASC30 in participants with diabetes. Enrollment is expected to begin in... |
| 15.12.2025 | Ascletis Announces Positive Topline Results from U.S. Phase I Study of ASC50, a Potential Best-in-Class Oral Small Molecule IL-17 Inhibitor | - The elimination half-life of ASC50 after a single oral dose was 43, 89, 91, 87, 104, and 85 hours for 10 mg, 30 mg, 100 mg, 200 mg, 400 mg, and 600 mg, respectively, supporting once-daily or potentially once-weekly oral dosing.
- ASC50 ha... |
| 10.12.2025 | Ascletis Announces China National Medical Products Administration Acceptance of New Drug Application for Denifanstat (ASC40), a First-in-Class FASN Inhibitor for Acne Treatment | -Denifanstat (ASC40) met all primary, key secondary and secondary efficacy endpoints (ITT analysis) and significantly improved moderate-to-severe acne vulgaris compared with placebo in a randomized, double-blind, placebo-controlled, multice... |
| 08.12.2025 | Ascletis' Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted Weight Loss of 7.7% with Better Gastrointestinal Tolerability in Its 13-Week U.S. Phase II Study in Participants with Obesity ... | - ASC30 once-daily tablets showed statistically significant and clinically meaningful dose-dependent placebo-adjusted mean body weight reductions with no observed plateau for weight loss.
- ASC30 titrated weekly to target dose demonstrated ... |
| 30.11.2025 | Ascletis Selects Its First Oral GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development | - Utilizing Ascletis' Peptide Oral Transport ENhancement Technology (POTENT), ASC37 oral tablets achieved average absolute oral bioavailability of 4.2%, approximately 9-, 30-, and 60-fold higher than semaglutide, tirzepatide, and retatrutid... |
| 13.11.2025 | Ascletis Announces Co-formulation of ASC36, Once-Monthly Next-Generation Amylin Receptor Agonist and ASC35, Once-Monthly Next-Generation GLP-1R/GIPR Dual Agonist for Clinical Development | - Using Ascletis' proprietary Ultra-Long-Acting Platform technology, co-formulation of ASC36, a once-monthly subcutaneously administered amylin receptor peptide agonist and ASC35, a once-monthly subcutaneously administered GLP-1R/GIPR dual ... |
| 05.11.2025 | Ascletis Presents Full Analysis of Phase Ib Study of ASC30 Oral Tablet, Phase Ib Study of ASC30 Injection, and Preclinical Study of Combination of ASC31 and ASC47 at ObesityWeek® 2025 | -Positive data from Phase Ib study of ASC30 oral tablet demonstrated up to 6.5% placebo-adjusted mean body weight reduction; safe and well tolerated with only mild-to-moderate gastrointestinal (GI) adverse events (AEs) across all multiple a... |
| 30.10.2025 | Ascletis Selects a Best-in-Class Once-Monthly Subcutaneously Administered Amylin Receptor Agonist, ASC36, for Clinical Development | -In head-to-head non-human primate (NHP) studies, average observed half-life of ASC36 was approximately 15 days, 3-fold longer than petrelintide, which supports once-monthly subcutaneous (SQ) dosing in humans.
-ASC36 demonstrated approximat... |
| 27.10.2025 | Ascletis to Present Study Results of ASC30 Oral Tablet, ASC30 Injection, and Combination of ASC31 and ASC47 at ObesityWeek® 2025 | -Multiple posters being presented on Ascletis' small molecule and peptide obesity programs
-Full analysis of 28-day multiple ascending dose study of oral GLP-1R small molecule agonist ASC30 as a late-breaking poster as well as ASC30 once-mo... |
| 20.10.2025 | Ascletis Completes Enrollment in U.S. Phase IIa Study for Its Once-Monthly Subcutaneous Depot Treatment Formulation of Small Molecule GLP-1R Agonist ASC30 for Obesity | - The 12-week U.S. Phase IIa study is evaluating the efficacy, safety and tolerability of the once-monthly subcutaneous (SQ) depot formulation (treatment formulation) of small molecule GLP-1 receptor (GLP-1R) agonist ASC30 in 65 participant... |
| 14.10.2025 | Ascletis Completes Denifanstat (ASC40) Pre-NDA Consultation with China National Medical Products Administration | - Denifanstat (ASC40) met all primary, key secondary and secondary efficacy endpoints (ITT analysis) and significantly improved moderate-to-severe acne vulgaris compared with placebo in a Phase III randomized, double-blind, placebo-controll... |
| 13.10.2025 | Ascletis Selects a Best-In-Class Once-Monthly Subcutaneously Administered GLP-1R/GIPR Dual Peptide Agonist, ASC35, for Clinical Development | - In head-to-head non-human primate (NHP) studies, average observed half-life of ASC35 was approximately 14 days, 6-fold longer than tirzepatide, which supports once-monthly subcutaneous (SQ) dosing in humans.
- In head-to-head NHP studies,... |
| 22.09.2025 | Ascletis Announces ASC47 in Combination with Semaglutide Demonstrated Up to 56.2% Greater Relative Reduction in Body Weight in Participants with Obesity Compared to Semaglutide Monotherapy | - The gastrointestinal (GI) tolerability of ASC47 in combination with semaglutide was significantly better than placebo in combination with semaglutide (semaglutide monotherapy). The incidence of vomiting was 6.7% in ASC47 in combination wi... |
| 18.09.2025 | Ascletis Presented Phase III Study Results of First-in-Class FASN Inhibitor Denifanstat (ASC40) for Acne Treatment in the Late Breaking News Sessions of the European Academy of Dermatology and Venereo... | --Denifanstat (ASC40) met all primary, key secondary and secondary efficacy endpoints (ITT analysis) and significantly improved moderate-to-severe acne compared with placebo.
--Denifanstat (ASC40) demonstrated a favorable safety and tolerab... |
| 17.09.2025 | Ascletis Presented Results from Cohorts 1 and 2 of 28-day Multiple Ascending Dose Study of Its Oral Small Molecule GLP-1R Agonist ASC30 at the 61st European Association for the Study of Diabetes (EASD... | - ASC30 once-daily oral tablet demonstrated up to 6.5% placebo-adjusted mean body weight reduction from baseline after 28-day treatment.
- ASC30 tablet's higher efficacy is supported by its higher oral drug exposures.
- ASC30 is safe and we... |
| 02.09.2025 | Ascletis to Present 28-day Multiple Ascending Dose Study Results of Oral Small Molecule GLP-1R Agonist ASC30 at the 61st European Association for the Study of Diabetes (EASD) Annual Meeting | - Ascletis to present data from the U.S. Phase Ib clinical study of ASC30 oral tablet in oral discussion
- On track to report topline data from Phase IIa clinical study of ASC30 oral tablet in participants with obesity or overweight in the ... |
| 28.08.2025 | Ascletis Announces Favorable and Differentiated Pharmacokinetic Profile of ASC30 Oral Once-Daily Tablet in Its U.S. Phase Ib Multiple Ascending Dose Study | - ASC30 oral once-daily tablet demonstrated approximately 2.3-fold to 3.3-fold greater drug exposure than orforglipron in a cross-trial comparison.
- Higher drug exposure and favorable tolerability profile positions ASC30 oral once-daily ta... |
| 18.08.2025 | Ascletis Announces the Combination of ASC47 and ASC31, its Dual GLP-1R/GIPR Peptide Agonist, Demonstrated Significantly Greater Weight Loss Compared to the Combination of ASC47 and Tirzepatide in an A... | - Combination of a low dose of ASC47 with ASC31, a novel peptide agonist targeting both GLP-1 receptor (GLP-1R) and GIP receptor (GIPR), resulted in a 44.8% reduction in body weight after 14 days of treatment in a diet-induced obese (DIO) m... |
| 13.08.2025 | Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, Demonstrated Greater Efficacy with Tirzepatide than Semaglutide in a Preclinical Model | - The combination of ASC47 low dose with tirzepatide in diet-induced obese (DIO) mice resulted in an 87% greater reduction in body weight compared to tirzepatide monotherapy.
- ASC47 low dose in combination with tirzepatide demonstrated sta... |
| 05.08.2025 | Ascletis Completes Enrollment in U.S. Phase IIa Study for Its Small Molecule Oral GLP-1R Agonist, ASC30, in Participants with Obesity or Overweight | - 13-week U.S. Phase IIa study is evaluating the efficacy, safety and tolerability of two oral formulations of ASC30, a once-daily tablet, in 125 participants with obesity or overweight.
- All 125 participants enrolled in just over one mont... |
| 28.07.2025 | Ascletis Announces First Participants with Obesity or Overweight Dosed in Its U.S. 12-week Phase IIa Study Evaluating Once-Monthly Subcutaneous Depot Formulation of Small Molecule GLP-1R Agonist ASC30 | - First participants with obesity or overweight with at least one weight-related comorbidity have been dosed in a U.S. 12-week Phase IIa study with once-monthly subcutaneous (SQ) depot formulation of small molecule GLP-1 receptor agonist AS... |
| 15.07.2025 | Ascletis Completes Dosing of All Participants in Its U.S. Clinical Study Combining Adipose-Targeted, Once-Monthly Injectable Small Molecule THRβ Agonist, ASC47, and Semaglutide for the Treatment of Ob... | - The combination study, conducted in the U.S., is designed to evaluate the safety, tolerability and preliminary efficacy at Day 29 of a single-dose of ultra-long-acting subcutaneously administered ASC47 (half-life up to 40 days) in combina... |
| 03.07.2025 | Ascletis Announces First Participants with Obesity or Overweight Dosed in a U.S. 13-week Phase IIa Study of Small Molecule Oral GLP-1R Agonist ASC30 | - First participants with obesity or overweight with at least one weight-related comorbidity have been dosed in a U.S. 13-week Phase IIa study of small molecule oral GLP-1 receptor agonist ASC30.
- ASC30 oral once-daily tablet demonstrated ... |
| 09.06.2025 | Ascletis Announces Poster Presentations on the Study Results of ASC30 and ASC47 at the 85th Scientific Sessions of American Diabetes Association (ADA) | HONG KONG, June 9, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that poster presentations on preliminary studies of its oral small molecule GLP-1 Receptor (GLP-1R) agonist ASC30 and adipose-targeted... |
| 20.05.2025 | Ascletis Announces First Participants Dosed in a U.S. Clinical Study Combining Adipose-Targeted, Once-Monthly Injectable Small Molecule THRβ Agonist, ASC47, and Semaglutide for the Treatment of Obesit... | - The combination study is designed to evaluate the safety and preliminary efficacy of a single-dose of ultra-long-acting subcutaneously administered ASC47 in combination with four doses of semaglutide (0.5 mg, once-weekly) in participants ... |
| 06.05.2025 | Ascletis Announces Oral and Poster Presentations on ASC47, an Adipose-Targeted, Muscle-Preserving Weight Loss Drug Candidate for Obesity at the 32nd European Congress on Obesity | HONG KONG, May 6, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces oral and poster presentations on preliminary studies of ASC47, an adipose-targeted, muscle-preserving weight loss drug candidate for obe... |
| 23.04.2025 | Ascletis Announces Positive Topline Results of U.S. Phase Ib Multiple Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30 and Submission of 13-week Phase IIa Study Protocol to FDA | - ASC30 oral once-daily tablet demonstrated a 6.5% placebo-adjusted mean body weight reduction from baseline after four-week treatment using weekly doses with titrations of 2 mg, 10 mg, 20 mg, and 40 mg doses.
- ASC30 oral once-daily tablet... |
| 03.04.2025 | New Frontiers in Obesity and Cancer Treatment: Ascletis and Telix Lead the Charge | In the ever-evolving landscape of medical innovation, two companies stand out this week: Ascletis Pharma and Telix Pharmaceuticals. Both are making strides in their respective fields—obesity treatment and cancer therapy. Their recent announ... |
| 31.03.2025 | Ascletis Announces Positive Interim Results from Its U.S. Phase Ib Trial with ASC30, a Potentially First-in-Class Subcutaneous Injection Small Molecule GLP-1R Agonist | -Ultra-long-acting subcutaneous (SQ) injection formulation of small molecule ASC30 demonstrated a 36-day half-life in patients with obesity, supporting once monthly or less frequent administration.
-As previously disclosed, oral tablet form... |
| 24.03.2025 | China’s biotech sector is undervalued given its AI-driven opportunities: Investor | - |
| 20.03.2025 | Ascletis Pharma to Host Obesity Portfolio Webinar on April 2, 2025 | HONG KONG, March 20, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces it will host an Obesity Portfolio Webinar on April 2, 2025, from 9:00 a.m. – 10:30 a.m. ET.
The event will include a detailed discuss... |
| 12.03.2025 | Ascletis Announces Positive Topline Results of Phase Ib Studies of ASC47 Monotherapy in Australia and U.S. FDA Clearance of IND Application for ASC47 in Combination with Semaglutide | ASC47, an adipose-targeted muscle-preserving weight loss drug candidate for the treatment of obesity, demonstrated a half-life of up to 26 days and 40 days, respectively, in Phase Ib single subcutaneous injection studies in healthy subjects... |
| 20.02.2025 | Promising Advances in Obesity and Glioblastoma Treatments: A Dual Spotlight on ASC30 and SI-053 | In the ever-evolving landscape of medical research, two companies have recently made headlines with their promising advancements in treatments for obesity and glioblastoma. Ascletis Pharma Inc. and Double Bond Pharmaceutical International A... |
| 19.02.2025 | Ascletis Announces Positive Interim Results from First Two Cohorts of U.S. Phase Ib Multiple Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30 | - ASC30 oral once-daily tablet demonstrated a 6.3% mean body weight reduction from baseline after 28-day treatment in multiple ascending dose (MAD) cohort 2 (weekly titrations of 2 mg, 10 mg, 20 mg, and 40 mg).
- ASC30 oral once-daily table... |
| 21.01.2025 | Ascletis Announces Positive Results from U.S. Phase Ia Single Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30 and Provides Program Update | ASC30 oral tablet demonstrated dose-proportional pharmacokinetic (PK) properties and a long half-life (t1/2) up to 60 hours in the single ascending dose (SAD) study of patients with obesity, supporting once-daily or less frequent oral dosin... |
| 20.12.2024 | New Frontiers in Obesity Treatment: ASC47 and Imlifidase Show Promise | In the battle against obesity and autoimmune diseases, two recent studies shine a light on innovative treatments that could change the landscape of medical care. Ascletis Pharma's ASC47 and Hansa Biopharma's imlifidase are making waves, eac... |
| 18.12.2024 | Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Pr... | In a head-to-head diet-induced obese (DIO) mouse study, ASC47 low dose combination 1 (ASC47, 3 mg/kg, subcutaneous (SQ), once every four weeks plus semaglutide, 30 nmol/kg, SQ, once daily), demonstrated superior weight loss compared to sema... |
| 12.11.2024 | Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne | -Phase III trial enrolled a total of 480 patients with moderate to severe acne
-Topline results expected in the second quarter 2025
HANGZHOU, China, Nov. 12, 2024 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today... |
| 09.11.2024 | The Future of Weight Loss: Ascletis' ASC47 and Tezspire's Breakthrough in Nasal Polyps | In the ever-evolving landscape of pharmaceuticals, two recent studies shine a light on innovative treatments that could reshape how we approach obesity and chronic rhinosinusitis with nasal polyps. Ascletis Pharma's ASC47 and AstraZeneca's ... |
| 07.11.2024 | Ascletis Announces Promising Results from a Phase I Study in Australia for First-in-Class Muscle-Preserving Weight Loss Drug Candidate ASC47 for the Treatment of Obesity | Data from a Phase I single ascending dose (SAD) study in Australia in subjects with elevated low-density lipoprotein cholesterol (LDL-C) showed that ASC47, via subcutaneous (SQ) injection, demonstrated a half-life of 21 days, supporting onc... |
| 17.09.2024 | Ascletis Enters the Obesity Drug Space with Announcement of Two Ongoing U.S. Phase I Clinical Trials Utilizing Its Small Molecule GLP-1R Agonist ASC30 for Both Once-Monthly Subcutaneous Injection and ... | - ASC30 is the first and only small molecule GLP-1 receptor (GLP-1R) agonist that can be dosed once-monthly subcutaneously and once-daily orally to treat obesity
- ASC30 is two- to threefold more potent, in vitro, than orforglipron and stim... |
| 11.06.2024 | Gannex Announces Poster Presentation of Positive Interim 12-Week Results from Phase II Clinical Trial of ASC41 in Patients with Biopsy-Confirmed MASH at EASL CONGRESS 2024 | --Up to 68.2% mean relative reduction in liver fat content from baseline among biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients receiving 12-week treatment of ASC41
--Significant and clinically meaningful re... |
| 03.04.2024 | Ascletis Announces Strategic Decisions on FXR agonist ASC42 | HANGZHOU, China and SHAOXING, China, April 3, 2024 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces today the strategic decisions on farnesoid X receptor (FXR) agonist ASC42.
After thorough analysis of the Ph... |
| 11.03.2024 | Ascletis Announces Poster Presentation of Phase II Study Final Results of FASN Inhibitor ASC40 for Treatment of Acne at 2024 AAD Annual Meeting | HANGZHOU and SHAOXING, China, March 11, 2024 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces the poster presentation of Phase II study final results of ASC40, a first-in-class fatty acid synthase (FAS... |
| 24.01.2024 | Ascletis Announces Dosing of the First Patient in Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne | HANGZHOU and SHAOXING, China, Jan. 24, 2024 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces dosing of the first patient in Phase III clinical trial of ASC40 (Denifanstat) for treatment of moderate to ... |
| 23.01.2024 | Gannex's Strategic Partner Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH | Denifanstat achieved statistically significant results on primary and multiple secondary endpoints in a 52-week clinical trial of 168 NASH patients with stage 2 or 3 fibrosis
- Primary efficacy endpoints:
NASH resolution without worsening o... |
| 05.12.2023 | Ascletis Announces Initiation of Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne | --The Phase III clinical trial of ASC40 for moderate to severe acne vulgaris will enroll 480 subjects
--The protocol of Phase III clinical trial has been agreed by Center for Drug Evaluation, National Medical Products Administration and obt... |
| 13.11.2023 | Ascletis Announces Poster Presentations at AASLD Annual Meeting 2023 Including a Late-Breaking Abstract of Interim Results from Phase IIb Expansion Cohort of ASC22 for Functional Cure of CHB | HANGZHOU and SHAOXING, China, Nov. 13, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces late-breaking abstract poster presentation of interim results from Phase IIb expansion cohort of ASC22 (Enva... |
| 09.11.2023 | Dr. Jinzi J. Wu Presents at the 10th International Workshop on HBV Cure 2023 | HANGZHOU and SHAOXING, China, Nov. 9, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces that Dr. Jinzi J. Wu, Founder, Chairman and CEO of Ascletis was invited to attend and have a presentation at ... |
| 06.11.2023 | Gannex Published Phase I Data of ASC42, a Novel Farnesoid X Receptor Agonist on the Journal Drugs in R&D | SHANGHAI, Nov. 6, 2023 /PRNewswire/ -- Gannex Pharma Co., Ltd. ("Gannex"), a wholly-owned company of Ascletis Pharma Inc. (HKEX:1672) announces today that the safety, pharmacokinetics (PK), and pharmacodynamics (PD) data of ASC42,... |
| 11.10.2023 | Ascletis Announces Poster Presentation of Phase II Study Topline Results of FASN Inhibitor ASC40 for Treatment of Acne at EADV Congress 2023 | HANGZHOU and SHAOXING, China, Oct. 11, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "Ascletis") today announces the poster presentation of Phase II study topline results of ASC40, a first-in-class fatty acid synthase (FAS... |
| 29.09.2023 | Ascletis Announces Positive Interim Data from the Phase IIb Expansion Cohort of ASC22 (Envafolimab) for Chronic Hepatitis B Functional Cure | HANGZHOU and SHAOXING, China, Sept. 29, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces positive interim data from the Phase IIb expansion cohort (the "Expansion Cohort") of subcutaneou... |
| 26.09.2023 | Ascletis Announces Completion of Enrollment of 120 Patients in the Phase III Clinical Trial of FASN Inhibitor ASC40 Combined with Bevacizumab for Treatment of Recurrent Glioblastoma | --Based on prespecified interim analysis condition, 120 patients are likely to lead sufficient events for interim analysis of progression-free survival (PFS)
HANGZHOU and SHAOXING, China, Sept. 26, 2023 /PRNewswire/ -- Ascletis Pharma Inc. ... |
| 05.09.2023 | Ascletis to Participate in the Upcoming Morgan Stanley 21st Annual Global Healthcare Conference | HANGZHOU and SHAOXING, China, Sept. 5, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that it will participate in the upcoming Morgan Stanley 21st Annual Global Healthcare Conference. John Gargi... |
| 25.07.2023 | Clinical Results of ASC22 (Envafolimab) in Combination with Chidamide for Functional Cure of HIV Infection Presented at the 12th IAS Conference on HIV Science | HANGZHOU and SHAOXING, China, July 25, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces that Shanghai Public Health Clinical Center presented clinical results of ASC22 (Envafolimab) in combination... |
| 20.07.2023 | Gannex Announces the Completion of Patient Enrollment for Phase II Clinical Trial of ASC42, an FXR Agonist, for Primary Biliary Cholangitis | -- Gannex is expected to release topline data of the Phase II clinical trial by the end of 2023
SHANGHAI, July 20, 2023 /PRNewswire/ -- Gannex Pharma Co., Ltd. ("Gannex"), a wholly-owned company of Ascletis Pharma Inc. (HKEX:1672)... |
| 26.06.2023 | Ascletis Announces Poster Presentation of Phase II Study of ASC42 FXR Agonist for Functional Cure of Chronic Hepatitis B at EASL CONGRESS 2023 | HANGZHOU and SHAOXING, China, June 26, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "Ascletis") today announces the poster presentation of ASC42, a novel farnesoid X receptor (FXR) agonist, in combination with PEGylated i... |
| 08.05.2023 | Ascletis Announces China NMPA Approval of Conducting a Phase IIa Clinical Trial for ASC10 to Treat Respiratory Syncytial Virus Infection | --Respiratory syncytial virus (RSV) infection treatment remains huge unmet medical needs and there is no effective drug for treatment globally so far
--Dosage of 800 mg ASC10, twice daily was selected to conduct a Phase IIa study in patient... |
| 02.05.2023 | Ascletis Announces ASC40, a First-in-Class, Once-Daily Oral FASN Inhibitor, Achieved Endpoints in Phase II Clinical Trial for Acne | HANGZHOU and SHAOXING, China, May 2, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that ASC40 (Denifanstat), a first-in-class, once-daily oral fatty acid synthase (FASN) inhibitor, achieved pri... |
| 27.02.2023 | Ascletis (1672.HK) Included in the Hang Seng Hong Kong-Listed Biotech Index | HANGZHOU and SHAOXING, China, Feb. 27, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that it will be included in the Hang Seng Hong Kong-Listed Biotech Index (Index code: HSHKBIO), effective fr... |
| 21.02.2023 | Ascletis Presented Positive Phase I Clinical Data for Broad-Spectrum Antiviral Double Prodrug ASC10 at CROI 2023 | --At the dosage of 800 mg ASC10, twice daily (BID), the exposure of the active drug, ASC10-A, is comparable to that of monupiravir's
--ASC10 at 800 mg, BID is safe and well tolerated
--Dosage of 800 mg ASC10, BID was selected for Phase IIa ... |
| 16.02.2023 | Oral Presentation at APASL Annual Meeting 2023 Demonstrates ASC22, a Subcutaneous PD-L1 Antibody, Can Achieve Functional Cure of Chronic Hepatitis B | HANGZHOU and SHAOXING, China, Feb. 16, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "Ascletis") today announces that the oral presentation at the 2023 annual meeting of the Asian Pacific Association for the Study of the L... |
| 31.01.2023 | Ascletis Announces U.S. FDA Approval of Conducting a Phase IIa Clinical Trial for ASC10 to Treat Respiratory Syncytial Virus Infection | --Respiratory syncytial virus (RSV) infection treatment remains huge unmet medical needs and there is no effective drug for treatment globally so far
--Dosage of 800 mg ASC10, twice daily was selected to conduct a Phase IIa study in patient... |
| 31.01.2023 | Ascletis Announces U.S. FDA Approval of Conducting a Phase IIa Clinical Trial for ASC10 to Treat Respiratory Syncytial Virus Infection | --Respiratory syncytial virus (RSV) infection treatment remains huge unmet medical needs and there is no effective drug for treatment globally so far
--Dosage of 800 mg ASC10, twice daily was selected to conduct a Phase IIa study in patient... |
| 26.01.2023 | Ascletis Announces IND Approval of Oral Viral Polymerase Inhibitor ASC10 for Monkeypox Indication by China NMPA | --Preclinical studies show that ASC10-A, the active metabolite of double prodrug ASC10, has potent antiviral activities against both monkeypox and SARS-CoV-2 viruses
--Ascletis has received the Notice of Issuance from the United States Pate... |
| 17.01.2023 | Ascletis Announces Entering into a Supply Agreement of Ritonavir Tablets with Simcere | HANGZHOU and SHAOXING, China, Jan. 17, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces that its wholly owned subsidiary Ascletis Pharmaceuticals Co., Ltd. has entered into a supply agreement of r... |
| 16.01.2023 | Ascletis Announces Dosing of 4 Healthy Subjects of the First Cohort in Multiple-Dose Escalation Phase I Clinical Trial of Oral 3CLpro Inhibitor ASC11 for COVID-19 | --The multiple-dose escalation Phase I clinical trial is expected to enroll 72 healthy subjects, and the enrollment is expected to be completed in the first quarter of 2023
--Ascletis has filed global patent applications for ASC11 and relat... |
| 02.01.2023 | Ascletis Believes that the Complaints Made by Viking Therapeutics Have No Merit and will Vigorously Defend Against such Complaints | HANGZHOU and SHAOXING, China, Jan. 2, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") was recently informed that on December 29, 2022, Viking Therapeutics, Inc. ("Viking"), a pharmaceutical company in ... |
| 02.01.2023 | Ascletis Believes that the Complaints Made by Viking Therapeutics Have No Merit and will Vigorously Defend Against such Complaints | HANGZHOU and SHAOXING, China, Jan. 2, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") was recently informed that on December 29, 2022, Viking Therapeutics, Inc. ("Viking"), a pharmaceutical company in ... |
| 21.12.2022 | Ascletis' NASH Drug ASC41(THRβ) Phase II Enrollment is Progressing as Planned | HANGZHOU and SHAOXING, China, Dec. 20, 2022 /PRNewswire/ -- The enrollment of the 52-week Phase II clinical trial of thyroid hormone receptor β (THRβ) agonist ASC41 developed in house by Gannex Pharma Co., Ltd., a wholly owned subsidiary of... |
| 21.12.2022 | Ascletis' NASH Drug ASC41(THRβ) Phase II Enrollment is Progressing as Planned | HANGZHOU and SHAOXING, China, Dec. 21, 2022 /PRNewswire/ -- The enrollment of the 52-week Phase II clinical trial of thyroid hormone receptor β (THRβ) agonist ASC41 developed in house by Gannex Pharma Co., Ltd., a wholly owned subsidiary of... |
| 19.12.2022 | Ascletis Announces Notice of Issuance of the U.S. Patent for Oral Viral Polymerase Inhibitor ASC10 and Its Derivatives | --The issue date of the patent will be January 3, 2023 by the United States Patent and Trademark Office (USPTO). The patent number is 11,541,071
-- The issued patent covers ASC10 and its derivatives, and their uses to treat virus infections... |
| 12.12.2022 | Ascletis Announces Positive Phase I Clinical Results of Oral RdRp Inhibitor ASC10 for COVID-19 | --The exposure of active drug ASC10-A after twice daily dosing 800 mg double prodrug ASC10 in Chinese subjects was 94% of that after twice daily dosing 800 mg single prodrug molnupiravir in Japanese subjects
--Based on Ascletis' Phase I res... |
| 07.12.2022 | Ascletis Announces IND Approval of Oral 3CLpro Inhibitor ASC11 for COVID-19 by China NMPA | --The objective of Phase I clinical trial is to identify a safe and efficacious dose for the pivotal Phase II/III in COVID-19 patients. Phase I clinical trial is expected to be completed within the first quarter of 2023
--Phase I clinical t... |
| 30.11.2022 | Ascletis Announces Completion of 180 Patient Enrollment for Phase II Clinical Trial of FASN Inhibitor ASC40 for Acne | --To date, approximately 50% enrolled patients have completed 12-week treatment and all enrolled patients are expected to complete 12-week treatment by the end of February 2023
-- Clinical efficacy observed in patients who have completed 12... |
| 29.11.2022 | Ascletis Announces IND Filing of Oral 3CLpro Inhibitor ASC11 for COVID-19 Accepted by China NMPA | HANGZHOU, China and SHAOXING, China, Nov. 29, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that the Investigational New Drug (IND) application of ASC11, an oral inhibitor drug candidate target... |
| 23.11.2022 | Ascletis Announces IND Approval of Oral 3CLpro Inhibitor ASC11 for COVID-19 by U.S. FDA | --The Phase I clinical trial will consist of 3 cohorts in healthy subjects, including single- and multiple-dose escalation studies and food effect study. The objective of Phase I trial is to find a right dose to move into the pivotal Phase ... |
| 17.11.2022 | Ascletis Announces IND Approval of Oral PD-L1 Small Molecule Inhibitor ASC61 for Treatment of Advanced Solid Tumors by China NMPA | --While the ASC61 Phase I study is ongoing in the U.S., the Investigational New Drug (IND) approval in China will accelerate the global development of ASC61, an in-house developed oral PD-L1 small molecule inhibitor
HANGZHOU and SHAOXING, C... |
| 16.11.2022 | Ascletis Announces IND Approval of Viral Polymerase Inhibitor ASC10 for Monkeypox Indication by U.S. FDA | --Based on available data, ASC10 at the dosage of 800 mg twice daily was approved by the U.S. Food and Drug Administration (FDA) to conduct a Phase Ib study in patients with monkeypox virus disease
--Preclinical studies show that ASC10-A, a... |
